HCM
TOVX icon

Heights Capital Management’s Theriva Biologics TOVX Stock Holding History

Heights Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-141,958
Closed -$196K – 159
2024
Q3 		$196K Buy
+141,958
New +$693K 0.15% 49

Other funds holding TOVX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IHWM
Iron Horse Wealth Management Johston, Iowa $339M AUM 10.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Heights Capital Management's TOVX Position: Q4 2024 in Review

Heights Capital Management sold out of Theriva Biologics (TOVX) in Q4 2024, closing a stake of 141,958 shares — an estimated $196K sold.

Heights Capital Management first reported a position in TOVX in Q3 2024 and held it in 1 quarter. The position peaked at $196K in Q3 2024. 10 funds tracked by Wall St. Rank hold TOVX as of Q4 2024.

  • Heights Capital Management reported no remaining Theriva Biologics position as of Q4 2024 after selling out during the quarter.
  • Heights Capital Management sold 141,958 Theriva Biologics shares in Q4 2024, an estimated $196K.
  • Heights Capital Management first reported a position in Theriva Biologics in Q3 2024 and held it in 1 quarter.
  • Heights Capital Management's Theriva Biologics position peaked at $196K in Q3 2024.
  • 10 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2024.

Based on Heights Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.